Survodutide: The GLP-1/Glucagon Dual Agonist Reshaping Metabolic Treatment

Review of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial results, and potential to reshape cardiometabolic disease treatment.

Arun, Amogh Jyothi et al.·Cardiology in review·2025·
RPEP-099922025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Review of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial results, and potential to reshape cardiometabolic disease treatment.

Key Numbers

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Review of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial re
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.
Published In:
Cardiology in review (2025)
Database ID:
RPEP-09992

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Review of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial results, and potential to reshape cardiometabolic disease treatment.

How reliable?

Consult publication.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-09992·https://rethinkpeptides.com/research/RPEP-09992

APA

Arun, Amogh Jyothi; Darji, Bhavika; Baig, Madiha; Frishman, William H; Aronow, Wilbert S. (2025). Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000001062

MLA

Arun, Amogh Jyothi, et al. "Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.." Cardiology in review, 2025. https://doi.org/10.1097/CRD.0000000000001062

RethinkPeptides

RethinkPeptides Research Database. "Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiom..." RPEP-09992. Retrieved from https://rethinkpeptides.com/research/arun-2025-survodutide-a-dual-glp1glucagon

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.